These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 32615109)

  • 1. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
    Mazzaferro V; Citterio D; Bhoori S; Bongini M; Miceli R; De Carlis L; Colledan M; Salizzoni M; Romagnoli R; Antonelli B; Vivarelli M; Tisone G; Rossi M; Gruttadauria S; Di Sandro S; De Carlis R; Lucà MG; De Giorgio M; Mirabella S; Belli L; Fagiuoli S; Martini S; Iavarone M; Svegliati Baroni G; Angelico M; Ginanni Corradini S; Volpes R; Mariani L; Regalia E; Flores M; Droz Dit Busset M; Sposito C
    Lancet Oncol; 2020 Jul; 21(7):947-956. PubMed ID: 32615109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
    Kelley RK; Rimassa L; Cheng AL; Kaseb A; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Banerjee K; Hazra S; Fawcett J; Yau T
    Lancet Oncol; 2022 Aug; 23(8):995-1008. PubMed ID: 35798016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
    Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
    Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
    Mazzaferro V; Llovet JM; Miceli R; Bhoori S; Schiavo M; Mariani L; Camerini T; Roayaie S; Schwartz ME; Grazi GL; Adam R; Neuhaus P; Salizzoni M; Bruix J; Forner A; De Carlis L; Cillo U; Burroughs AK; Troisi R; Rossi M; Gerunda GE; Lerut J; Belghiti J; Boin I; Gugenheim J; Rochling F; Van Hoek B; Majno P;
    Lancet Oncol; 2009 Jan; 10(1):35-43. PubMed ID: 19058754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies.
    Lei J; Yan L
    J Gastrointest Surg; 2012 Nov; 16(11):2120-5. PubMed ID: 22948843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
    Llovet JM; Pavel M; Rimola J; Diaz MA; Colmenero J; Saavedra-Perez D; Fondevila C; Ayuso C; Fuster J; Ginès P; Bruix J; Garcia-Valdecasas JC
    Liver Transpl; 2018 Mar; 24(3):369-379. PubMed ID: 29140601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
    Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
    Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria.
    Gunsar F
    Exp Clin Transplant; 2017 Mar; 15(Suppl 2):59-64. PubMed ID: 28302001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?
    Cascales-Campos P; Martinez-Insfran LA; Ramirez P; Ferreras D; Gonzalez-Sanchez MR; Sanchez-Bueno F; Robles R; Pons JA; Capel A; Parrilla P
    Transplant Proc; 2018 Mar; 50(2):591-594. PubMed ID: 29579861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
    Kim Y; Stahl CC; Makramalla A; Olowokure OO; Ristagno RL; Dhar VK; Schoech MR; Chadalavada S; Latif T; Kharofa J; Bari K; Shah SA
    Surgery; 2017 Dec; 162(6):1250-1258. PubMed ID: 29033224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
    Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver-Directed Combined Radiation Therapy for Downstaging Beyond-Milan Hepatocellular Carcinoma to Liver Transplantation.
    Kim J; Kim YT; Lee JG; Han DH; Joo DJ; Kim DY; Seong J
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1171-1178. PubMed ID: 38364951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.